Finally, considering the whole cohort receiving CTLA4-Ig, RA patients having pre-treatment IL-6 serum levels ≤ 8.4 pg/ml and CD4posCD25posFoxP3pos cell rate ≥ 6.0% had the highest rate of DAS-remission at 6 months (90.0%) compared to RA patients having just one (IL-6 serum levels ≤ 8.4: 33.3%, p = 0.011 or CD4posCD25posFoxP3pos cell rate ≥ 6.0%: 20.0%, p = 0.007) or none of these features (12.5%, p = 0.001) (Fig. 4E). Here, IL6 is linked to rheumatoid arthritis.